CORD-19:12d35c12218f230c49f4dc892814ba9f1037f251 / 61066-61290 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/CORD-19/sourceid/12d35c12218f230c49f4dc892814ba9f1037f251","sourcedb":"CORD-19","sourceid":"12d35c12218f230c49f4dc892814ba9f1037f251","text":"A clinical trial investigating the propensity of inducing Treg development through the use of an anti-CD28 super-agonist antibody (TGN1412) resulted in six human volunteers experiencing life-threatening complications (179) .","tracks":[{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T53","span":{"begin":0,"end":224},"obj":"Sentence"}],"attributes":[{"subj":"T53","pred":"source","obj":"CORD-19_Custom_license_subset"}]},{"project":"CORD-19-Sentences","denotations":[{"id":"T72822","span":{"begin":0,"end":224},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"attributes":[{"subj":"T72822","pred":"source","obj":"CORD-19-Sentences"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"CORD-19_Custom_license_subset","color":"#93a7ec","default":true},{"id":"CORD-19-Sentences","color":"#c1ec93"}]}]}}